Plant-based nutraceutical interventions against cognitive impairment and dementia: Meta-analytic evidence of efficacy of a standardized Gingko biloba extract

Journal of Alzheimer's Disease

Volumn 43, Issue 2, 2015, Pages 605-611

  Solfrizzi, Vincenzo ^a,b   Panza, Francesco ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b Geriatric Unit   (Italy)

Author keywords

Alzheimer's disease; cognitive impairment; dementia; EGb 761; Gingko biloba extract; meta analysis; mild cognitive impairment; nutraceuticals; systematic review

Indexed keywords

BETA CAROTENE; CARNOSIC ACID; CAROTENOID; CURCUMIN; DAIDZEIN; DITERPENE; EPICATECHIN; FLAVANONE; FLAVONOID; GENISTEIN; GINKGO BILOBA EXTRACT; KAEMPFEROL; LYCOPENE; MALVIDIN CHLORIDE; NARINGENIN; NUTRACEUTICAL; PELARGONIDIN; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; XANTHOPHYLL; PLANT EXTRACT;

ALZHEIMER DISEASE; CELL METABOLISM; COGNITIVE DEFECT; DEMENTIA; DRUG BIOAVAILABILITY; FUNCTIONAL STATUS; HUMAN; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; REVIEW; SYSTEMATIC REVIEW; ANIMAL; CHEMISTRY; DIET SUPPLEMENTATION; DIET THERAPY; GINKGO BILOBA; PHYTOTHERAPY;

ANIMALS; COGNITION DISORDERS; DEMENTIA; DIETARY SUPPLEMENTS; GINKGO BILOBA; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84911933095     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141887     Document Type: Review

References (49)

1. Bolognesi ML, Matera R, Minarini A, Rosini M, MelchiorreC (2009) Alzheimer's disease: New approaches to drug discovery. Curr Opin Chem Biol 13, 303-308.
2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodiesagainst amyloid-peptide enter the central nervous systemand reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919.
3. Morgan D (2005) Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis 2, 261-266.
4. Panza F, Logroscino G, Imbimbo BP, Solfrizzi V (2014) Isthere still any hope for amyloid-based immunotherapy forAlzheimer's disease? Curr Opin Psychiatry 27, 128-137.
5. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab 301, 302Clinical Trial, Investigators (2014) Two phase 3 trials of bapineuzumabin mild-to-moderate Alzheimer's disease. N Eng J Med 370, 322-333.
6. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease CooperativeStudy Steering Committee, Solanezumab Study, Group (2014) Phase 3 trials of solanezumab for mild-to-moderateAlzheimer's disease. N Engl J Med 370, 311-321.
7. Costantino L, Barlocco D (2012) Designed multiple ligands:Basic research vs clinical outcomes. Curr Med Chem 19, 3353-3387.
8. Geldenhuys WJ, Van der Schyf CJ (2013) Designing drugswith multitarget activity: The next step in the treatment ofneurodegenerative disorders. Expert Opin Drug Discov 8, 115-129.
9. Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L (2012) Dementia prevention: Current epidemiological evidenceand future perspective. Alzheimers Res Ther 4, 6.
10. The European Dementia Prevention Initiative, http://www.edpi.org/
11. Farás GA, Guzmán-Martńez L, Delgado C, Maccioni RB (2014) Nutraceuticals: A Novel concept in prevention andtreatment of Alzheimer's disease and related disorders. J Alzheimers Dis 42, 357-367.
12. Frisardi V, Panza F, Seripa D, Imbimbo BP, Vendemiale G, Pilotto A, Solfrizzi V (2010) Nutraceutical properties ofMediterranean diet and cognitive decline: Possible underlyingmechanisms. J Alzheimers Dis 22, 715-740.
13. Mecocci P, Tinarelli C, Schulz RJ, Polidori MC (2014) Nutraceuticals in cognitive impairment and Alzheimer's disease. Front Pharmacol 5, 147.
14. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, KurzA (2010) Efficacyof a medical food in mild Alzheimer's disease:Arandomized, controlled trial. Alzheimers Dement 6, 1-10. e1.
15. Chan A, Remington R, Kotyla E, Lepore A, Zemianek J, SheaTB (2010) Avitamin/nutriceutical formulation improvesmemory and cognitive performance in community-dwellingadults without dementia. J Nutr Health Aging 14, 224-230.
16. Richter Y, Herzog Y, Eyal I, Cohen T (2011) Cognitex supplementationin elderly adults with memory complaints: Anuncontrolled open label trial. J Diet Suppl 8, 158-168.
17. Carrasco-Gallardo C, Farias GA, Fuentes P, Crespo F, MaccioniRB (2012) Can nutraceuticals prevent Alzheimer'sdisease? Potential therapeutic role of a formulation containingshilajit and complex B vitamins. Arch Med Res 43, 699-704.
18. Wang J, Bi W, Cheng A, Freire D, Vempati P, Zhao W, Gong B, Janle EM, Chen TY, Ferruzzi MG, Schmeidler J, Ho L, Pasinetti GM (2014) Targeting multiple pathogenic mechanismswith polyphenols for the treatment of Alzheimer'sdisease-experimental approach and therapeutic implications. Front Aging Neurosci 6, 42.
19. Anand R, Gill KD, Mahdi AA (2014) Therapeutics ofAlzheimer's disease: Past, present and future. Neuropharmacology 76 Pt A, 27-50.
20. Gross G, Jacobs DM, Peters S, Possemiers S, van Duynhoven J, Vaughan EE, Gross G, Jacobs DM, Peters S, Possemiers S, van Duynhoven J, Vaughan EE (2010) In vitro bioconversionof polyphenols from black tea and red wine/grape juice byhuman intestinal microbiota displays strong interindividualvariability. J Agric Food Chem 58, 10236-10246.
21. Howes M-JR, Houghton PJ (2009) Traditional medicine formemory enhancement. In: Herbal Drugs: Ethnomedicine toModern Medicine, Ramawat KG, ed. Springer, New York, pp. 239-291.
22. Koch E (2005) Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides:Considerations on possible bleeding complications after oralintake of Ginkgo biloba extracts. Phytomedicine 12, 10-16.
23. Koltermann A, Hartkorn A, Koch E, Fürst R, Vollmar AM, Zahler S (2007) Ginkgo biloba extract EGb 761 increasesendothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci 64, 1715-1722.
24. Ramassamy C, Christen Y, Clostre F, Costentin J (1992) The Ginkgo biloba extract, EGb761, increases synaptosomaluptake of 5-hydroxytryptamine: In-vitro and ex-vivo studies. J Pharm Pharmacol 44, 943-945.
25. Fehske CJ, Leuner K, Müller WE (2009) Ginkgo bilobaextract (EGb761) influences monoaminergic neurotransmissionvia inhibition of NE uptake, but not MAO activity afterchronic treatment. Pharmacol Res 60, 68-73.
26. Yoshitake T, Yoshitake S, Kehr J (2010) The Ginkgo bilobaextract EGb 761(R) and its main constituent flavonoids andginkgolides increase extracellular dopamine levels in the ratprefrontal cortex. Br J Pharmacol 159, 659-668.
27. DeFeudis FV, Drieu K (2000) Ginkgo biloba extract (EGb761) and CNS functions: Basic studies and clinical applications. Curr Drug Targets 1, 25-58.
28. Rangel-Ordonez L, Noldner M, Schubert-Zsilavecz M, WurglicsM (2010) Plasma levels and distribution of flavonoidsin rat brain after single and repeated doses of standardizedGinkgo biloba extract EGb 761(R) . Planta Med 76, 1683-1690.
29. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R (2000) The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced bybeta-amyloid. Eur J Neurosci 12, 1882-1890.
30. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P (2002) Inhibitionof amyloid-beta aggregation and caspase-3 activation bythe Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 99, 12197-12202.
31. Tchantchou F, Xu Y, Wu Y, Christen Y, LuoY (2007) EGb761enhances adult hippocampal neurogenesis and phosphorylationof CREB in transgenic mouse model of Alzheimer'sdisease. FASEB J 21, 2400-2408.
32. Schneider LS (2012) Ginkgo and AD: Key negatives andlessons from GuidAge. Lancet Neurol 11, 836-837.
33. Canter PH, Ernst E (2007) Ginkgo biloba is not a smart drug:An updated systematic review of randomised clinical trialstesting the nootropic effects of G. biloba extracts in healthypeople. Hum Psychopharmacol 22, 265-278.
34. Oken BS, Storzbach DM, Kaye JA (1998) The efficacy ofGinkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55, 1409-1415.
35. Birks J, Grimley EV, Van Dongen M (2002) Ginkgo bilobafor cognitive impairment and dementia. Cochrane Database Syst Rev 4, CD003120.
36. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M (2005) A randomized, double-blind, placebocontrolledtrial of two doses of Ginkgo biloba extract indementia of the Alzheimer's type. Curr Alzheimer Res 2, 541-551.
37. Birks J, Grimley Evans J (2007) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2, CD003120.
38. Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitiveimpairment and dementia. Cochrane Database Syst Rev 1, CD003120.
39. McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen MJ, Warner J (2008) Ginkgo biloba for mildto moderate dementia in a community setting: A pragmatic, randomised, parallel-group, double-blind, placebo-controlledtrial. Int J Geriatr Psychiatry 23, 1222-1230.
40. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD, Ginkgo Evaluation ofMemory (GEM) Study, Investigators (2008) Ginkgo bilobafor prevention of dementia: A randomized controlled trial. JAMA 300, 2253-2262.
41. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S, Guid Age Study, Group (2012) Long-term use of standardised Ginkgo biloba extractfor the prevention of Alzheimer's disease (GuidAge) : A randomisedplacebo-controlled trial. Lancet Neurol 11, 851-859.
42. Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O (2011) Efficacy and safety ofa once-daily formulation of Ginkgo biloba extract EGb 761in dementia with neuropsychiatric features: A randomizedcontrolled trial. Int J Geriatr Psychiatry 26, 1186-1194.
43. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S (2012) Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety ofa daily dose of 240 mg. J Psychiatr Res 46, 716-723.
44. Gavrilova SI, Preuss UW, Wong JW, Hoerr R, Kaschel R, Bachinskaya N (2014) Efficacy and safety of Ginkgo bilobaextract EGb 761 in mild cognitive impairment with neuropsychiatricsymptoms: A randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry. doi:10. 1002/gps. 4103
45. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN (2010) Effects of Ginkgo biloba in dementia: Systematicreview and meta-analysis. BMC Geriat 10, 14.
46. Brondino N, De Silvestri A, Re S, Lanati N, Thiemann P, Verna A, Emanuele E, Politi P (2013) Asystematic reviewandmeta-analysis of Ginkgo biloba in neuropsychiatric disorders:From ancient tradition to modern-day medicine. Evid BasedComplement Alternat Med 2013, 915691.
47. Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, Jiang T, Zhu XC, Tan L (2014) Efficacy and adverse effects of Ginkgobiloba for cognitive impairment and dementia: A systematicreview and meta-analysis. J Alzheimers Dis 43, 589-603.
48. Napryeyenko O, Borzenko I, Study GINDEM-NP, Group (2005) Ginkgo biloba special extract in dementia with neuropsychiatricfeatures. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 57, 4-11.
49. Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G (2014) Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward. Expert Rev Clin Immunol 10, 405-419.